Denmark Sweden Norway Finland  Genzyme Danmark HomeKontaktGenzyme Corporate Home
OM OS
BEHANDLINGSOMRÅDER
PRODUKTER
Genzyme  
Genzyme er ét af verdens førende bioteknologiske firmaer og vores mål, er at forbedre livet for patienter med alvorlige sygdomme. Læs mere her
 
NYHEDER
PRESSEMEDDELSE
European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules


Copenhagen, Denmark - Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Cerdelga® (eliglustat) capsules, an oral treatment for certain adults living with Gaucher disease type 1.
Mere >
PRESSEMEDDELSE
Genzyme’s Lemtrada (alemtuzumab) Approved by the FDA


CAMBRIDGE, Mass. - November 14, 2014 - Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
Mere >
PRESSEMEDDELSE
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis


Cambridge, Mass. - Nov. 4, 2014 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme’s investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs. placebo in RRMS patients. The safety, tolerability and pharmacokinetics of vatelizumab will also be assessed.
Mere >

genzyme i
norden
genzyme
biosurgery
genzyme
corporation
 

Terms and Conditions Privacy Policy © 2008 Genzyme. All Rights Reserved. Webmaster